Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF

CoMentis

Status and phase: Completed; Phase 2

Conditions: Age-Related Macular Degeneration

Treatments: Drug: Placebo; Drug: ATG003 (mecamylamine)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00607750

ATG003-203

Details and patient eligibility

About

This study is a double-masked, randomized, placebo-controlled study of the safety and preliminary efficacy of ATG003 (topical mecamylamine) in patients receiving maintenance injections of either ranibizumab or bevacizumab. Study Hypothesis: Mecamylamine could be effective in the treatment of neovascular AMD.

Enrollment: 60 patients

Sex: All

Ages: 56+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• > 55 years of age
• clinical diagnosis of neovascular AMD

Exclusion criteria

• confounding ocular condition

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

60 participants in 2 patient groups, including a placebo group

1

Placebo Comparator group

Treatment:

Drug: Placebo

ATG003

Experimental group

Treatment:

Drug: ATG003 (mecamylamine)